Canche AA, Garza EVA, Rodríguez WF

Language: Spanish
References: 19
Page: 25-32
PDF size: 78.17 Kb.

ABSTRACT

Platelet dysfunction is a major bleeding cause in surgical patients with normal preoperative and coagulation tests. Platelet dysfunction may be associated to congenital platelet disorders, storage pool problems or to platelet function acquired diseases, usually related to several drug or substance use. An easy way to detect these alterations in high-risk patients is through an aggregometry assay, being a low-cost and easy-to-interpret lab test.

REFERENCES

1. Bithell TC. The physiology of primary hemostasis. In: Wintrobe´s Clinical Hematology. 9a ed. Lee GA, et al. Philadelphia. 1993.

2. Montiel MG. VIII. Hemostasia Primaria. Gac Méd Méx 2003; 139(2): 95-97.

3. Michelson AD. Current options in platelet function testing. The American Journal of Cardiology. Elsevier Inc 2006; 98(10): S4-S10.

4. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.

5. A Widi A. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. Department of Medicine, Hemostasis and Thrombosis Laboratory, Faculty of Medicine. Jordan 2009; 20(5): 297-301.

6. Natasha Ali. Diagnostic tool for Glanzmann’s thrombasthenia clinicopathologic spectrum. Journal of the College of Physicians and Surgeons—Pakistan: JCPSP. 01/03/2008; 18(2): 91-4.

7. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.

8. Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. Br J Haematol 2006; 133: 251-8.

9. Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2006.

10. Utility of PFA-100® closure time vs optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro. Professor Mojca Stegnar Clinical Chemical Laboratory Medicine. 2007; 45(11): 1542–1548.

11. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005; 5: 399-408.

12. Ghosh K. Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function. 2003; 13(6): 351-354(4).

13. Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 2007; 5 (1): 157-166.

14. Mezzano D. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. 2009; 35(2): 242-54. Epub 2009 Apr 30.

15. The pharmacological basis of therapeutics. Goodman & Guilman. 21th ed. Editor McGraw-Hill; 2008.

16. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, Minford A, Mumford AD, Parapia LA, Perry DJ, Watson SP, Wilde JT, Williams MD; UKHCDO. Review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol, 2006; 135(5): 603-33.

17. The results of CAPRIE, IST and CAST. Clopidogrel vs aspirin in patients at risk of ischaemic events. International Stroke Trial. Chinese Acute Stroke Trial. Dippel DW. Department of Neurology, University Hospital Rotterdam, The Netherlands. 1998; 92(1 Suppl 1): S13-6.

18. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.

19. Kaye AD, Lucera I, Sabar R. Preoperative anesthesia: clinical considerations of alternative medicine. Anesthesiol Clin N Am 2004; 22: 125-139.